Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer? Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 8, 2007, Pages 460-461

  Hammel, Pascal ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; SHORT SURVEY; SURVIVAL TIME;

EID: 34548585587     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0884     Document Type: Short Survey

References (4)

1. Bakkevold KE et al. (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29: 698-703
2. Takada T et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685-1695
3. Kosuge T et al. (2006) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 36: 159-165
4. Neoptolemos JP et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210